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Material and Methods: A retrospective analysis of 
prospective data was performed on patients with locally 
advanced NSCLC treated with radiotherapy. Three dose 
groups were defined based on EQD2,T (A: < 50 Gy, B: 50-55 
Gy, C: > 55 Gy). The primary endpoint was involved nodal 
relapse (INR). An actuarial Kaplan-Meier analysis was 
performed to evaluate the cumulative proportion of INR and 
primary tumor progression per dose group. 
 
Results: From 2006 to 2010, 75 consecutive patients were 
included in this study. Groups A, B and C consisted of 22, 24 
and 29 patients respectively. Median follow-up was 7 months. 
All patient characteristics were well balanced between the 3 
dose groups. A total of 142 lymph nodes were included in the 
analysis (A: 49; B: 36; C: 57). Any relapse 
(locoregional/distant) occurred in 58 patients (77%). INR was 
observed in 18% in group A, 8% in group B and 14% in group C. 
No dose-response relationship was observed in the involved 
LN (p=0.35). Primary tumor progression was seen in 55%, 42% 
and 28% in group A, B and C respectively. A significant dose-
response relationship was observed in the primary tumor 
(p=0.02). Baseline nodal diameter was not associated with 




The results of this study suggest that LN control can be 
achieved at lower radiation dose than needed for the primary 
tumor. Prospective dose de-escalation studies on LN are 
needed to decrease incidence of severe oesophagitis without 
compromising local control. 
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Purpose or Objective: The CC Chemokine Ligand 18 (CCL18) 
is produced by alveolar macrophages in patients with 
fibrosing lung disease and its concentration is increased in 
various inflammatory and fibrotic lung diseases. In this study 
we aimed to analyze the role of CCL18 as a potential 
prognostic biomarker for the development of radiation 
induced lung disease (RILD) after thoracic irradiation. 
 
Material and Methods: Between August 2011 and February 
2012, 60 patients were enrolled prospectively in the study. 
Forty-six patients were treated for lung cancer; thirteen had 
an esophageal cancer and one a thymoma. Patients were 
treated either with conventionally fractionated (n=47) or 
hypo-fractionated (n=13) radiotherapy, 9 patients were 
treated adjuvant, 3 neoadjuvant, 4 with palliative intent and 
44 with a definitive radiochemotherapy. The CCL18 levels in 
serum were quantified with ELISA (enzyme-linked 
immunosorbent assay) at predefined time points; before 
treatment, after 30 Gy, after 60 Gy (for conventional 
fractionation), at 6 weeks after completion of treatment and 
3 months after therapy. These results were then correlated 
with clinical signs of RILD routinely performed computed 
tomographies (CTs) at 6 weeks and 3 months after the last 
treatment. 
 
Results: Twenty three patients developed radiologic signs of 
RILD but only three of them developed symptoms. The mean 
CCL18 levels, for the whole group of patients, were before 
treatment 110 ng/ml (standard deviation, + 53) and at the 
end of treatment 85 ng/ml (+ 73). During the first (6 weeks 
after treatment) and second follow-up (3 months after 
treatment) the mean CCL18 levels were 93 ng/ml (+ 57) and 
104 ng/ml (+ 49), respectively. The CCL18 concentrations in 
serum were not significantly elevated in the group of patients 
who developed a RILD. The mean CCL18 levels at six weeks 
and three months after treatment were in the RILD-group 94 
ng/ml (+ 62) and 104 ng/ml (+ 61) and in the non-RILD-group 
93 ng/ml (+ 54) and 103 ng/ml (+ 39). Patients with elevated 
CCL18 over the mean had a slightly worse local control 
(p=0,047) and a slightly worse overall survival which didn’t 
reach statistical significance. 
 
Conclusion: These findings do not suggest that the 
chemokine CCL18 is involved in the development of RILD in 
patients undergoing radiotherapy for chest tumors. 
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Purpose or Objective: In the present study we have 
evaluated local control, overall survival (OS) and toxicity of 
re-irradiation with stereotactic body radiation therapy (SBRT) 
in patients with recurrent/progressive primary or secondary 
lung tumors after previous radical radiation therapy or SBRT. 
 
Material and Methods: Between August 2011 and December 
2014, 9 patients (6 men and 3 women) received a second 
course of SBRT in single (23 Gy or 30 Gy) or multiple fractions 
(15 Gy x 3). The median volume was 19.8 cc (range 3,7 - 46,8 
cc). The median interval from previous irradiation was 18 
months (range 12 - 47 months). Previous treatment included 
radical radiation therapy (60 Gy) in 33% of lesions and single-
fraction SBRT (23 Gy or 30 Gy) in 67% of lesions. 
 
Results: The median follow-up was 11 months (range 2 – 38 
months). The median OS after the second course of SBRT was 
12 months (range 3 – 39 months). The 6- and 12-months 
survival rates were 100% and 88%, respectively. No patient 
developed grade ≥ 2 t oxicity. Complete response was 
observed in 2 patients (22%) and stable disease in 6 patients 
(66%). One patient died for progressive systemic disease. 
 
Conclusion: Re-irradiation with SBRT for 
recurrent/progressive primary or secondary lung tumors is a 
feasible treatment associated with good local control and 
acceptable toxicity 
 
 
